SCHEMBL65165

SCHEMBL65165

N#Cc1ccc(C(=O)O)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HA1 P13674 3/20 0.55
P4HTM Q9NXG6 2/20 0.55
MIF P14174 1/20 0.53
GABRP O00591 1/20 0.52
GABRD O14764 1/20 0.52
GABRA1 P14867 1/20 0.52
GABRB1 P18505 1/20 0.52
GABRG2 P18507 1/20 0.52
GABRB3 P28472 1/20 0.52
GABRA5 P31644 1/20 0.52
GABRA3 P34903 1/20 0.52
GABRA2 P47869 1/20 0.52
GABRB2 P47870 1/20 0.52
GABRA4 P48169 1/20 0.52
GABRE P78334 1/20 0.52
GABRA6 Q16445 1/20 0.52
GABRG1 Q8N1C3 1/20 0.52
GABRG3 Q99928 1/20 0.52
GABRQ Q9UN88 1/20 0.52
NAPRT Q6XQN6 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31281693 1.00 P4HA1 (0.55) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL1169257 0.85 MAP4K4 (0.52) HSD17B10KCNQ3KCNQ2XDHCHEK1
Hydrochloric Acid SCHEMBL5611433 0.84 GABRP (0.42) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL1584376 0.82 MAPT (0.49) ALDH1A1HPGDKCNQ3KCNQ2MAPT
SCHEMBL2515153 0.82 KCNQ3 (0.46) P4HA1P4HTMKCNQ3KCNQ2CHEK1
SCHEMBL1993840 0.82 GRM5 (0.58) ALDH1A1KCNQ3KCNQ2MKNK2GRM5
SCHEMBL19580190 0.82 KCNQ3 (0.46) P4HA1P4HTMKCNQ3KCNQ2CHEK1
SCHEMBL3868436 0.82 KCNQ3 (0.46) P4HA1P4HTMNAPRTKCNQ3KCNQ2
SCHEMBL29470887 0.82 P4HA1 (0.48) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL5163246 0.82 P4HA1 (0.57) P4HA1P4HTMMIFGABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 536 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
EP-4720060-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2026-04-08 EP disclosed
EP-4709795-A1 PRETARGETED BIMODAL IMAGING AGENTS Københavns Universitet (DK) 2026-03-18 EP disclosed
WO-2025215153-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2025-10-16 WO disclosed
WO-2025202864-A1 ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER iTeos Belgium SA (BE) 2025-10-02 WO disclosed
US-20250276967-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES SIGNAL PHARMACEUTICALS, LLC 2025-09-04 US disclosed
US-12338235-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CELGENE CORPORATION (US) 2025-06-24 US disclosed
EP-4570798-A1 AROMATIC HETEROCYCLIC CYCLOHEXYL AMINOALKYL PIPERIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF Jiangsu NHWA Pharmaceutical Co., Ltd (CN) 2025-06-18 EP disclosed
WO-2025104613-A1 ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS iTeos Belgium SA (BE) 2025-05-22 WO disclosed
CN-119677734-A Aromatic heterocyclic cyclohexane amino alkyl piperidine derivative, preparation method and application thereof 江苏恩华药业股份有限公司 2025-03-21 CN disclosed
WO-1996022288-A1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS ELI LILLY AND COMPANY (US) 1996-07-25 WO disclosed
US-5399585-A Anitcoagulants, antiinflammatory, antitumor HOFFMANN-LA ROCHE INC. (US) 1995-03-21 US disclosed
EP-0381033-B1 Carboxylic-acid and sulphonic-acid amides HOFFMANN LA ROCHE (CH) 1994-03-23 EP disclosed
US-5256812-A Antitumor agents, cardiovascular disorders; having amidino or guandino groups HOFFMANN-LA ROCHE INC. (US) 1993-10-26 US disclosed
US-5084466-A Anticoagulants, antiinflammatory agents, atheriosclerosis and antitumor agents HOFFMANN-LA ROCHE INC. (US) 1992-01-28 US disclosed
US-4904675-A Phamacologically active 5-carboxy-2-(5-tetrazolyl) pyridines ZYMA SA (CH) 1990-02-27 US disclosed
EP-0278908-A2 Heterocyclic compounds Zyma SA (CH) 1988-08-17 EP disclosed
EP-0091464-B1 METHOD FOR THE PREPARATION OF CYANO-HETEROCYCLES SCHERING AKTIENGESELLSCHAFT (DE) 1986-04-16 EP disclosed
EP-0091464-A1 METHOD FOR THE PREPARATION OF CYANO-HETEROCYCLES. SCHERING AG (DE) 1983-10-19 EP disclosed
WO-1983001446-A1 METHOD FOR THE PREPARATION OF CYANO-HETEROCYCLES VORBRÜGGEN, Helmut 1983-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250276967-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CYP8B1, HAX1, HRH4 P4HA1 92/4885P4HTM 236/4885MIF 2073/4885
US-12338235-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CYP8B1, HAX1, HRH4 P4HA1 92/4885P4HTM 236/4885MIF 2073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.